Payment overview · 2025
General Payments
$374.91
3 reported records · 3 companies
Healthcare provider profile · identity verified
Ellen N Zagrebelsky, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · PHILADELPHIA, PA · NPI 1275584807
Verified facts
What the public records show
CMS Open Payments records show Ellen N Zagrebelsky, MD received $374.91 in general payments during 2025 across 3 reported records.
Phathom Pharmaceuticals, Inc. accounted for 33.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $125.00 | 33.3% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $124.99 | 33.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $124.92 | 33.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $374.91 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $124.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 325 | 48 |
| Atorvastatin Calcium | Atorvastatin Calcium | 325 | 74 |
| Ezetimibe | Ezetimibe | 247 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 211 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 189 | 36 |
| Gabapentin | Gabapentin | 183 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 179 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 179 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 171 | 37 |
| Vascepa | Icosapent Ethyl | 171 | 28 |
| Linzess | Linaclotide | 153 | 27 |
| Doxazosin Mesylate | Doxazosin Mesylate | 145 | 31 |
| Losartan Potassium | Losartan Potassium | 144 | 30 |
| Metformin Hcl | Metformin Hcl | 144 | 27 |
| Omeprazole | Omeprazole | 141 | 28 |
| Furosemide | Furosemide | 138 | 26 |
| Lisinopril | Lisinopril | 137 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 133 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 119 | 20 |
| Levothyroxine Sodium | Levothyroxine Sodium | 119 | 26 |
| Creon | Lipase/Protease/Amylase | 116 | 26 |
| Carvedilol | Carvedilol | 108 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 106 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 97 | 20 |
| Eliquis | Apixaban | 91 | 18 |
| Valsartan | Valsartan | 89 | 12 |
| Meloxicam | Meloxicam | 84 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 78 | 15 |
| Januvia | Sitagliptin Phosphate | 74 | 13 |
| Ammonium Lactate | Ammonium Lactate | 72 | 14 |
| Tradjenta | Linagliptin | 71 | suppressed |
| Allopurinol | Allopurinol | 70 | 12 |
| Meclizine Hcl | Meclizine Hcl | 66 | 16 |
| Potassium Chloride | Potassium Chloride | 66 | suppressed |
| Synthroid | Levothyroxine Sodium | 65 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | suppressed |
| Irbesartan | Irbesartan | 61 | suppressed |
| Simvastatin | Simvastatin | 61 | 11 |
| Donepezil Hcl | Donepezil Hcl | 58 | 13 |
| Mirtazapine | Mirtazapine | 58 | suppressed |
| Famotidine | Famotidine | 54 | suppressed |
| Atenolol | Atenolol | 53 | suppressed |
| Spironolactone | Spironolactone | 51 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 50 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 49 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 48 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 47 | suppressed |
| Celecoxib | Celecoxib | 46 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 46 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 43 | suppressed |
| Bumetanide | Bumetanide | 43 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 41 | 12 |
| Finasteride | Finasteride | 39 | suppressed |
| Glimepiride | Glimepiride | 39 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 39 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 38 | suppressed |
| Nifedipine Er | Nifedipine | 38 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 37 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 37 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 35 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 35 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 34 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 34 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 34 | suppressed |
| Lidocaine | Lidocaine | 33 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | suppressed |
| Nitroglycerin | Nitroglycerin | 31 | suppressed |
| Ranolazine Er | Ranolazine | 31 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Methimazole | Methimazole | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Cilostazol | Cilostazol | 26 | suppressed |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 25 | suppressed |
| Telmisartan | Telmisartan | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Ketoconazole | Ketoconazole | 24 | suppressed |
| Prednisone | Prednisone | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Alprazolam | Alprazolam | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Repaglinide | Repaglinide | 20 | suppressed |
| Brilinta | Ticagrelor | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 18 | suppressed |
| Bystolic | Nebivolol Hcl | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Proctozone-Hc | Hydrocortisone | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Restasis | Cyclosporine | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $374.91 · 3 records | Phathom Pharmaceuticals, Inc. | KISUNLA, VOQUEZNA, ZENPEP | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error